Abstract
The aim of this study was to investigate the efficacy and safety of minocycline (MIN) and favipiravir combination therapy in patients with coronavirus disease 2019 (COVID-19) admitted to our hospital in Fukui Prefecture, Japan, in March and April of 2020. In this retrospective study, a favipiravir monotherapy group (Control group, n = 9) was compared with a combined favipiravir plus MIN therapy group (MIN group, n = 12). No severe cases were present. The primary comparative endpoints evaluated were duration of fever, duration of hospitalization, duration from treatment initiation to severe acute respiratory syndrome coronavirus 2 polymerase chain reaction (PCR)-negative results, and changes in cytokine and chemokine production. Median duration from start of treatment to negative PCR test was significantly shorter in the MIN group than in the Control group. Mean rates of cytokine and chemokine reduction were significantly greater for interleukin-6 and interleukin-8 in the MIN group. No difference in adverse event rates were seen between groups, and only minor adverse events were encountered. MIN has been reported to have not only broad antibacterial activity, but also antiviral and anti-inflammatory activity. The present results support the efficacy and safety of MIN plus favipiravir therapy for the treatment of COVID-19.
Keywords: COVID-19; Favipiravir; Inflammatory cytokines; Minocycline; SARS-CoV-2.
【저자키워드】 COVID-19, SARS-CoV-2, Favipiravir, Inflammatory cytokines, Minocycline, 【초록키워드】 Treatment, coronavirus disease, SARS-CoV-2, Coronavirus disease 2019, coronavirus, therapy, Cytokines, Antiviral, hospital, interleukin-8, interleukin-6, Favipiravir, combination therapy, cytokine, severe acute respiratory syndrome Coronavirus, anti-inflammatory activity, chemokine, Retrospective study, polymerase chain reaction, interleukin, adverse event, Patient, Control, severe cases, Japan, Efficacy and safety, Inflammatory cytokines, PCR test, monotherapy, Minocycline, Chain Reaction, antibacterial activity, Support, reduction, acute respiratory syndrome, Endpoint, control group, no difference, Severe case, Negative PCR, treatment initiation, duration of hospitalization, cytokine and chemokine production, polymerase chain, greater, significantly, reported, evaluated, changes in, groups, duration of fever, MIN, significantly shorter, 【제목키워드】 therapy, Favipiravir, Minocycline,